Shanghai Medicine has no intention to expand production of Duffy

On the 15th, as an “authentic” Tamiflu production company, related parties of the Shanghai Pharmaceutical and Investor Relations Department revealed that the company’s production of Duffy was normal and its reserves were abundant enough to respond to government procurement. In addition, the company will not increase production or increase related investment.

The National Health and Family Planning Commission released two versions of the “Human Infection Plan for Human Infection with H7N9 Avian Flu”, which showed that there was no vaccine against H7N9 bird flu virus at home and abroad, but the virus was sensitive to anti-influenza virus drugs against neuraminidase inhibitors. The neuraminidase inhibitor may use Oseltamivir (Tamiflu).

Tamiflu's original research drug company is Roche Pharmaceuticals, currently Roche has no production in the country. According to the above-mentioned persons from Shanghai Pharmaceuticals, the company's controlling shareholder Shanghai Pharmaceutical Group is the first company in China to obtain Roche's authorized production of Tamiflu.

In the situation where H7N9 cases are still increasing, whether Duffy will be collected and stored on a large scale and whether it can play an active preventive and control effect has become the focus of attention of all parties. Yesterday, Dr. Gao Weiyi, deputy director of public health at the Shanghai CDC, told reporters that the Shanghai Health System is conducting an in-depth study on the clinical treatment of the H7N9 epidemic and is expected to establish a standardized and scientific prevention and control system in a relatively short period of time. According to him, Tamiflu has a good effect on early detection when treating H7N9 cases, but the treatment effect on severe patients, especially complications, is not obvious. He also said that Shanghai's Tamiflu reserves are sufficient to respond to the epidemic.

After Beijing's first case of human infection with the H7N9 bird flu case was confirmed, Beijing deployed ten countermeasures overnight, including halting live bird trade and storing 2 million copies of Tamiflu.

In Zhejiang, the relevant person in charge of the Zhejiang Pharmaceutical Pharmacy Procurement Center revealed at the beginning of April that the Zhejiang government had started purchasing from Tamiflu. In addition, Hubei Province also announced that it has stockpiled 3 million H7N9 testing reagents and rescue medicines.

According to Yang Fan, deputy director of the clinical application department of the Institute of Antibiotics at Shanghai Huashan Hospital, it is appropriate to stockpile some anti-drug drugs. The amount of Duffy who receives and stores 2 million people in Beijing is not too small. The government’s determination to prevent the H7N9 epidemic is significant.

As for Dongguang Aluminum, yesterday's daily limit was limited by Beijing’s Tamiflu incident. It is understood that Yichang Dongyang Pharmaceutical Co., Ltd., which holds a 7.4% stake, has more than 10 million Tamiflu reserves. However, company related sources said that it is expected that sales of Tamiflu will have little impact on the company's performance this year.